The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells

Published:2011-04-08 Issue:7 Volume:25 Page:1182-1188
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Asano J,Nakano A,Oda A,Amou H,Hiasa M,Takeuchi K,Miki H,Nakamura S,Harada T,Fujii S,Kagawa K,Endo I,Yata K,Sakai A,Ozaki S,Matsumoto T,Abe M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201160.pdf

Reference20 articles.

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC . Multiple myeloma. Lancet 2009; 374: 324–339.

2. Roodman GD . Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab 2010; 28: 244–250.

3. Matsumoto T, Abe M . Bone destruction in multiple myeloma. Ann N Y Acad Sci 2006; 1068: 319–326.

4. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004; 104: 2484–2491.

5. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 2004; 64: 2016–2023.

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy;Cell Communication and Signaling;2024-06-11

2. Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib;International Journal of Hematology;2024-01-22

3. Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors;International Journal of Hematology;2024-01-21

4. Advances in research on potential inhibitors of multiple myeloma;European Journal of Medicinal Chemistry;2023-12

5. RIPK2: a promising target for cancer treatment;Frontiers in Pharmacology;2023-05-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3